Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
乳可舒胶囊剂量探索与安慰剂对照治疗乳腺增生(肝郁痰凝、冲任失调证)
[Translation] Dose exploration of Rukeshu capsules and placebo control in the treatment of breast hyperplasia (liver depression and phlegm stagnation, Chong and Ren disorders)
1. 进一步评价乳可舒胶囊治疗乳腺增生(肝郁痰凝、冲任失调证)的有效性。 2. 为确定Ⅲ期临床试验的给药剂量提供依据; 3. 评价乳可舒胶囊的安全性。
[Translation] 1. To further evaluate the effectiveness of Rukeshu capsule in treating breast hyperplasia (liver depression and phlegm stagnation, Chong and Ren meridians disorder syndrome). 2. To provide a basis for determining the dosage for Phase III clinical trials; 3. To evaluate the safety of Rukeshu capsule.
乳可舒胶囊剂量探索与安慰剂对照治疗乳腺增生(肝郁痰凝、冲任失调证)
[Translation] Dose exploration of Rukeshu capsules and placebo control in the treatment of breast hyperplasia (liver depression and phlegm stagnation, Chong and Ren disorders)
1. 初步评价乳可舒胶囊治疗乳腺增生(肝郁痰凝、冲任失调证)的有效性。
2. 为确定Ⅲ期临床试验的给药剂量提供依据。
3. 评价乳可舒胶囊的安全性。
[Translation] 1. To preliminarily evaluate the effectiveness of Rukeshu Capsules in treating breast hyperplasia (liver depression and phlegm stagnation, Chong and Ren meridians disorder syndrome).
2. To provide a basis for determining the dosage for Phase III clinical trials.
3. To evaluate the safety of Rukeshu Capsules.
100 Clinical Results associated with Shaanxi Licai Pharmaceutical Co Ltd.
0 Patents (Medical) associated with Shaanxi Licai Pharmaceutical Co Ltd.
100 Deals associated with Shaanxi Licai Pharmaceutical Co Ltd.
100 Translational Medicine associated with Shaanxi Licai Pharmaceutical Co Ltd.